ModifiedUnitedHealthcarePolicy 2026D0043Y

Tocilizumab (Actemra, Tofidence, Tyenne) Injection for Intravenous Infusion - Medical Benefit Coverage Criteria

Medical benefit coverage criteria for intravenous tocilizumab products (Actemra, Tofidence, Tyenne) for UnitedHealthcare commercial plans, describing preferred products, prior authorization expectations, and diagnosis-specific medical necessity criteria for multiple rheumatologic indications.

Policy Summary

PayerUnitedHealthcare

PolicyTocilizumab (Actemra, Tofidence, Tyenne) Injection for Intravenous Infusion - Medical Benefit Coverage Criteria

Policy CodePolicy 2026D0043Y

Change TypeModified — added non‑preferred product designationterminology and example updates

Effective DateMar 1, 2026

Next Review DateN/A

Key ActionSubmit prior authorization with diagnosis-specific documentation and prescriber attestations as required; non‑listed FDA‑approved tocilizumab products will be treated as non‑preferred and may require additional review.

SourceLink

POLICY UPDATE CHANGES

Added language to indicate any U.S. Food and Drug Administration approved tocilizumab product not listed by name in this policy will be considered non-preferred until reviewed by UnitedHealthcare.

Replaced references to 'Targeted immunomodulator' with 'systemic targeted immunomodulator' and 'Biologic or targeted synthetic DMARD' with 'systemic targeted immunomodulator'.

Updated lists of example systemic targeted immunomodulators previously treated for rheumatoid arthritis and lists of agents not to be used in combination with tocilizumab for certain indications.

Updated CMS and references sections to reflect the most current information.

3preferred products named

6+indications with explicit criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

12 monthsauth duration cap

5+distinct clinical indications

03/01/2026revision date

Coverage Criteria for Intravenous Tocilizumab

Polyarticular Juvenile Idiopathic Arthritis

Covered when ALL of the following are met:

PJIA initial: Diagnosis of polyarticular juvenile idiopathic arthritis (PJIA); Tocilizumab is dosed according to FDA labeled dosing for PJIA; patient is not receiving Tocilizumab in combination with a systemic targeted immunomodulator (e.g., adalimumab, certolizumab, etanercept, baricitinib, abatacept, upadacitinib, golimumab, tofacitinib) for the same indication; prescriber attestation that the patient or caregiver are not able to be trained or are physically unable to administer Tocilizumab for self-administration (prescriber must submit explanation); prescribed by or in consultation with a rheumatologist; initial authorization is for no more than 12 months

Initial therapy criteria as stated in policy

PJIA continuation: Patient has previously received Tocilizumab injection for intravenous infusion; documentation of positive clinical response to Tocilizumab; Tocilizumab is dosed according to FDA labeled dosing for PJIA; patient is not receiving Tocilizumab in combination with a systemic targeted immunomodulator (e.g., adalimumab, certolizumab, etanercept, baricitinib, abatacept, upadacitinib, golimumab, tofacitinib) for the same indication; authorization is for no more than 12 months

Continuation therapy criteria as stated in policy

Rheumatoid Arthritis

Covered when ALL of the following are met:

RA initial: Diagnosis of moderately to severely active rheumatoid arthritis; history of failure, contraindication, or intolerance to at least one non-biologic DMARD OR prior treatment with a systemic targeted immunomodulator FDA‑approved for RA OR patient is currently on Tocilizumab; Tocilizumab is dosed according to FDA labeled dosing for RA; patient is not receiving Tocilizumab in combination with a systemic targeted immunomodulator (e.g., adalimumab, certolizumab, etanercept, baricitinib, abatacept, upadacitinib, golimumab, tofacitinib) for the same indication; prescriber attestation if patient/caregiver cannot self-administer (prescriber must submit explanation); prescribed by or in consultation with a rheumatologist; initial authorization is for no more than 12 months

Initial RA pathway includes OR options for prior therapies

RA continuation: Patient has previously received Tocilizumab injection for intravenous infusion; documentation of positive clinical response; prescriber attestation if patient/caregiver cannot self-administer (prescriber must submit explanation); Tocilizumab is dosed according to FDA labeled dosing for RA; patient is not receiving Tocilizumab in combination with a systemic targeted immunomodulator for the same indication; authorization is for no more than 12 months

Continuation therapy criteria as stated in policy

Systemic Juvenile Idiopathic Arthritis

Covered when ALL of the following are met:

SJIA initial: Diagnosis of systemic juvenile idiopathic arthritis (SJIA); Tocilizumab is dosed according to FDA labeled dosing for SJIA; patient is not receiving Tocilizumab in combination with a systemic targeted immunomodulator (e.g., adalimumab, certolizumab, etanercept, baricitinib, abatacept, upadacitinib, golimumab, tofacitinib) for the same indication; prescriber attestation if patient/caregiver cannot self-administer (prescriber must submit explanation); prescribed by or in consultation with a rheumatologist; initial authorization is for no more than 12 months

Initial therapy criteria as stated in policy

SJIA continuation: Patient has previously received Tocilizumab injection for intravenous infusion; documentation of positive clinical response to Tocilizumab; prescriber attestation if patient/caregiver cannot self-administer (prescriber must submit explanation); Tocilizumab is dosed according to FDA labeled dosing for SJIA; patient is not receiving Tocilizumab in combination with a systemic targeted immunomodulator for the same indication; authorization is for no more than 12 months

Continuation therapy criteria as stated in policy

Giant Cell Arteritis

Covered when ALL of the following are met:

GCA initial: Diagnosis of giant cell arteritis (GCA); Tocilizumab is dosed according to FDA labeled dosing for GCA; patient is not receiving Tocilizumab in combination with a systemic targeted immunomodulator (e.g., sarilumab, abatacept, upadacitinib) for the same indication; prescriber attestation if patient/caregiver cannot self-administer (prescriber must submit explanation); prescribed by or in consultation with a rheumatologist; initial authorization is for no more than 12 months

Initial therapy criteria as stated in policy

GCA continuation: Patient has previously received Tocilizumab injection for intravenous infusion; documentation of positive clinical response to Tocilizumab; prescriber attestation if patient/caregiver cannot self-administer (prescriber must submit explanation); Tocilizumab is dosed according to FDA labeled dosing for GCA; patient is not receiving Tocilizumab in combination with a systemic targeted immunomodulator for the same indication; authorization is for no more than 12 months

Continuation therapy criteria as stated in policy

Giant Cell Arteritis (GCA)

Tocilizumab is proven and medically necessary for giant cell arteritis when ALL of the following are met (distinct initial and continuation criteria):

Initial therapy (standard): Diagnosis of giant cell arteritis; Tocilizumab is dosed according to FDA label for GCA; patient is not receiving Tocilizumab in combination with another systemic targeted immunomodulator for the same indication; initial authorization no more than 12 months

Standard initial pathway

Continuation therapy (standard): Previously received Tocilizumab injection for intravenous infusion; documentation of positive clinical response; Tocilizumab is dosed according to FDA label for GCA; patient is not receiving Tocilizumab in combination with another systemic targeted immunomodulator for the same indication; authorization no more than 12 months

Standard continuation pathway

Initial therapy (when patient cannot self-administer): Diagnosis of GCA; prescriber attestation that patient or caregiver cannot be trained or are physically unable to self-administer (prescriber must submit explanation); Tocilizumab is dosed according to FDA label for GCA; patient is not receiving Tocilizumab in combination with another systemic targeted immunomodulator for the same indication; prescribed by or in consultation with a rheumatologist; initial authorization no more than 12 months

Guideline and Regulatory-Supported Indications

Tocilizumab is proven and medically necessary for CRS when ALL of the following are met:

Initial therapy: Diagnosis of cytokine release syndrome (CRS); patient has received CAR T-cell therapy or CD3-directed therapy; Tocilizumab is dosed according to FDA labeled dosing for CRS; initial authorization is for no more than 4 doses

Initial CRS criteria require prior CAR T-cell or CD3-directed therapy

Self-administered subcutaneous formulations of Actemra and Tyenne are typically obtained under the pharmacy benefit and are not covered under this medical benefit policy unless the member's benefit plan documents specify otherwise. An exception applies for members enrolled in UnitedHealthcare of California plans with a delegated provider group conducting the prior authorization review; in that situation, available self-administered tocilizumab products may be obtained under the medical benefit.

Tocilizumab must not be used concurrently with another systemic targeted immunomodulator for the same indication. Examples of systemic targeted immunomodulators that should not be given in combination with tocilizumab include Kevzara (sarilumab), Orencia (abatacept), and Rinvoq (upadacitinib); requests will be evaluated only when the patient is not receiving combination systemic targeted immunomodulator therapy.

Coverage for experimental, investigational, or unproven uses is determined by the member-specific Certificate of Coverage and applicable state mandates. Consult the member's benefit plan documentation to determine whether an off-label or investigational use may be covered under the plan or required by state law; such plan- or state-level provisions supersede the medical policy language.

UnitedHealthcare identifies Actemra (tocilizumab) and Tyenne (tocilizumab-aazg) as the preferred intravenous tocilizumab products. Any U.S. Food and Drug Administration–approved tocilizumab product that is not explicitly named in this policy will be considered non-preferred until reviewed by UnitedHealthcare.

Use of a non-preferred tocilizumab product (for example, Tofidence or other non-preferred biosimilars) requires meeting the criteria specified for non-preferred products. Coverage of non-preferred products is contingent on either documented intolerance or contraindication to preferred products with clinician attestation that the non-preferred product is expected to be effective/tolerated, or completion of the required trial period of preferred products as defined in the preferred-product criteria.

Requests for non-preferred tocilizumab that do not meet the preferred product criteria (trial of preferred products or documented intolerance/contraindication plus required attestation) may not meet coverage requirements and are subject to denial.

Coding and Diagnosis Codes

HCPCS / Procedure CodesHCPCSCovered

J3262	Injection, tocilizumab, 1 mg
Q5133	Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg
Q5135	Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg

GVHD and CRS ICD-10 CodesICD-10Covered

D89.810	Acute graft-versus-host disease
D89.831	Cytokine release syndrome, grade 1
D89.832	Cytokine release syndrome, grade 2
D89.833	Cytokine release syndrome, grade 3
D89.834	Cytokine release syndrome, grade 4
D89.835	Cytokine release syndrome, grade 5
D89.839	Cytokine release syndrome, grade unspecified

Rheumatoid Arthritis: M05 series (selected)ICD-10Covered

M05.A	Abnormal rheumatoid factor and anti-citrullinated protein antibody with rheumatoid arthritis
M05.00	Felty's syndrome, unspecified site
M05.011	Felty's syndrome, right shoulder
M05.012	Felty's syndrome, left shoulder
M05.019	Felty's syndrome, unspecified shoulder
M05.021	Felty's syndrome, right elbow
M05.022	Felty's syndrome, left elbow
M05.029	Felty's syndrome, unspecified elbow
M05.031	Felty's syndrome, right wrist
M05.032	Felty's syndrome, left wrist

1–10 of 17

1/2

Rheumatoid Arthritis: M05 series (selected continued)ICD-10Covered

M05.061	Felty's syndrome, right knee
M05.062	Felty's syndrome, left knee
M05.069	Felty's syndrome, unspecified knee
M05.071	Felty's syndrome, right ankle and foot
M05.072	Felty's syndrome, left ankle and foot
M05.079	Felty's syndrome, unspecified ankle and foot
M05.09	Felty's syndrome, multiple sites
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder

1–10 of 14

1/2

Juvenile Rheumatoid Arthritis: M08 series (required codes)ICD-10Covered

M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot

1–10 of 64

1/7

Additional Relevant ICD-10 CodesICD-10Covered

M31.5	Giant cell arteritis with polymyalgia rheumatica
M31.6	Other giant cell arteritis
T45.1X5A	Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
T45.1X5D	Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
T45.1X5S	Adverse effect of antineoplastic and immunosuppressive drugs, sequela
T80.82XA	Complication of immune effector cellular therapy, initial encounter
T80.82XD	Complication of immune effector cellular therapy, subsequent encounter
T80.82XS	Complication of immune effector cellular therapy, sequela
T80.89XA	Other complications following infusion, transfusion and therapeutic injection, initial encounter
T80.89XD	Other complications following infusion, transfusion and therapeutic injection, subsequent encounter

1–10 of 21

1/3

DAS28-ESR Thresholdmixed

DAS28-ESR < 2.6

Remission threshold used in ACT-RAY trial

Prior Authorization and Provider Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for all tocilizumab products. Initial authorizations for diagnosis-specific indications are generally limited to no more than 12 months unless otherwise specified; short-course authorizations apply for cytokine release syndrome (CRS) and acute graft‑versus‑host disease (GVHD) (see limits below). Continuation authorizations require documentation of prior benefit or positive clinical response and adherence to FDA‑labeled dosing for the requested indication.

Initial authorization limits: generally ≤ 12 months for chronic indications (e.g., RA, GCA, SJIA, PJIA); ≤ 4 doses for CRS and steroid-refractory acute GVHD; ≤ 4 doses for ICI‑related toxicities.
Continuation authorization: documentation of prior IV tocilizumab administration (when applicable), positive clinical response, and dosing consistent with FDA label; authorization periods typically limited to ≤ 12 months for chronic indications.
Requests exceeding the limits noted above (for example, >12 months for GCA or >4 doses for CRS/GVHD/ICI‑toxicity) may be denied without additional medical necessity justification.

Documentation Required

Clinical Background and Evidence Summary

This policy addresses intravenous formulations of tocilizumab (Actemra, Tofidence, Tyenne) and provides medical-benefit coverage criteria for multiple rheumatologic indications including polyarticular and systemic juvenile idiopathic arthritis, rheumatoid arthritis, and giant cell arteritis. Self-administered subcutaneous tocilizumab products are handled under the pharmacy benefit in most plans and are not the focus of this medical-benefit policy.

Definitions and Key Terms

inv-43: Tocilizumab (policy term)

Policy definition'Tocilizumab' refers to all tocilizumab products covered under this policy (Actemra, Tofidence, Tyenne) and applies to intravenous formulations addressed in this document.

Formulation scopeApplies specifically to intravenous infusion products; self-administered subcutaneous Actemra and Tyenne are typically under the pharmacy benefit unless specified by plan.

Product examplesActemra (tocilizumab), Tofidence (tocilizumab-bavi), Tyenne (tocilizumab-aazg)

inv-44: Cytokine Release Syndrome (CRS)

DefinitionCytokine release syndrome (CRS) is an inflammatory syndrome that can occur after CAR T-cell or CD3-directed therapies.

Prior authorization prerequisiteCoverage requires documentation that the patient received prior CAR T-cell therapy or CD3-directed therapy (e.g., Kymriah, Yescarta, Blincyto, Tecvayli) and dosing per FDA label.

Policy Revision History

03/01/2026policy_revisionLatest

Revised coverage rationale and preferred product language: any FDA‑approved tocilizumab product not listed by name in this policy will be considered non‑preferred until reviewed by UnitedHealthcare; terminology updates replacing 'Targeted immunomodulator' and 'Biologic or targeted synthetic DMARD' with 'systemic targeted immunomodulator'; updated example lists of systemic targeted immunomodulators for rheumatoid arthritis and lists of agents not to be used in combination with tocilizumab for select indications.

03/01/2026supporting_info_update

Updated supporting information sections including CMS and References to reflect the most current information.

Step therapy language in the policy was revised to clarify terminology and examples used in diagnosis-specific criteria. The policy replaces prior terms with “systemic targeted immunomodulator” and updates example agents listed for sequencing and prior-treatment requirements. Clinical context (including ACT-RAY trial findings and the 2021 ACR RA guideline) is referenced to support the policy's approach to DMARD sequencing and treat-to-target strategies when documenting prior therapies.

Policy Summary

PayerUnitedHealthcare

PolicyTocilizumab (Actemra, Tofidence, Tyenne) Injection for Intravenous Infusion - Medical Benefit Coverage Criteria

Policy CodePolicy 2026D0043Y

Change TypeModified — added non‑preferred product designationterminology and example updates

Effective DateMar 1, 2026

Next Review DateN/A

SourceLink

On This Page

Alternative pathway when self-administration is not possible

Continuation therapy (when patient cannot self-administer): Previously received Tocilizumab injection for intravenous infusion; documentation of positive clinical response; prescriber attestation that patient or caregiver cannot be trained or are physically unable to self-administer (prescriber must submit explanation); Tocilizumab is dosed according to FDA label for GCA; patient is not receiving Tocilizumab in combination with another systemic targeted immunomodulator for the same indication; authorization no more than 12 months

Continuation when self-administration is not possible

Diagnosis Codes for Prior Authorization

When requesting prior authorization include applicable ICD‑10 diagnosis codes that support the medical necessity of tocilizumab for the requested indication. Use the member-specific plan benefits and state mandates when determining coverage applicability.

Examples of applicable diagnosis codes are included in the policy (selected RA, juvenile arthritis, GCA, CRS and complication codes such as T80.82XA, T86.5, M31.5, M31.6, M05.x, M06.x, M08.x).
Include the specific ICD‑10 code(s) that match the member's documented diagnosis when submitting the PA request.

Prior Authorization

Prior Authorization/Review for Non‑Preferred Tocilizumab

Any U.S. FDA‑approved tocilizumab product not explicitly named in this policy will be considered non‑preferred until reviewed by UnitedHealthcare. Prior authorization/review is required for non‑preferred tocilizumab products.

Non‑listed tocilizumab products are treated as non‑preferred pending medical review (per Summary of Changes 03/01/2026).
Requests for non‑preferred products should include clinical rationale for use and supporting documentation as outlined below.

Step Therapy

Non‑Preferred Product Trial / Attestation Requirement

For certain non‑preferred tocilizumab biosimilars or formulations, documentation of a trial or prescriber attestation is required prior to approval.

Either documentation of a trial of at least 14 weeks of Actemra or another listed tocilizumab product with minimal clinical response and residual disease activity plus prescriber attestation that the patient would respond better to the non‑preferred product, or
Documentation of intolerance/contraindication/adverse event to Actemra or another listed tocilizumab product plus prescriber attestation that the same issue would not be expected with the non‑preferred product.
Patient must not have had loss of a favorable response after established maintenance therapy with a listed tocilizumab product.

Denial Risk

Authorization Limits and Dose Caps

Authorization limits vary by indication and are enforced at point of review. Requests that exceed standard authorization lengths or dose counts require strong documentation and may be denied.

Chronic indications (RA, GCA, SJIA, PJIA): initial and continuation authorizations typically ≤ 12 months.
Cytokine release syndrome (CRS): initial and continuation authorizations limited to ≤ 4 doses; prior CAR T‑cell or CD3‑directed therapy documentation required.
Steroid‑refractory acute GVHD: initial and continuation authorizations limited to ≤ 4 doses.
Immune checkpoint inhibitor (ICI)‑related toxicities: authorization limited to ≤ 4 doses; documentation required of no improvement after 7 days of high‑dose corticosteroids and prior failure/contraindication to infliximab.

Note

Benefit Plan and State Mandate Constraints

Coverage is subject to the member's benefit plan and any applicable state mandates. Where state law or a member's certificate of coverage requires different coverage (e.g., mandated off‑label coverage or coverage for investigational treatments under specific conditions), those requirements supersede the policy.

Consult the member-specific benefit plan document to determine whether experimental/investigational/unproven treatments or off‑label uses are covered for life‑threatening illnesses.
State mandates that require coverage for off‑label medication use or other exceptions will supersede this medical policy when applicable.

Denial Risk

Non‑Preferred Product Review Risk

Non‑preferred tocilizumab products that are FDA‑approved but not named in this policy are subject to UnitedHealthcare review and may be considered non‑preferred until a medical review is completed.

The policy update (03/01/2026) clarifies that any FDA‑approved tocilizumab product not listed by name will be treated as non‑preferred pending review.
Providers should expect prior authorization review for these products and include rationale and supporting documentation with the request.

Documentation Required

Prior Therapy Documentation (CRS and Related Indications)

Specific prior therapy documentation is required for indications tied to prior treatments (e.g., CRS). Include documentation of prior cellular or targeted therapies where required.

Cytokine release syndrome (CRS): submit documentation that the patient received CAR T‑cell therapy (e.g., Kymriah, Yescarta) or CD3‑directed therapy (e.g., blinatumomab, teclistamab) prior to tocilizumab.
Include procedure dates, facility/provider, and any relevant complication codes (e.g., T80.82XA/T80.82XD/T80.82XS) when available.

Documentation Required

Clinical Evidence and Disease Activity Documentation

Support prior authorization requests with clinical evidence of disease activity, response measures, and documentation consistent with guideline and trial endpoints when relevant.

Provide documentation of clinical response or disease activity measures where applicable (for RA, consider DAS28‑ESR or other validated measures; for juvenile arthritis and SJIA/PJIA provide relevant activity assessments).
Cite relevant trial data or guideline recommendations (e.g., ACT‑RAY trial, 2021 ACR RA guideline) when using sequencing or treat‑to‑target strategies to justify escalation to tocilizumab.
For continuation requests, include documentation of positive clinical response and objective evidence supporting ongoing benefit.

Note

Support with FDA Labeling and Policy Revision

When preparing documentation, reference FDA labeling and policy revision notes to align dosing and indication claims with approved indications and the policy's recent updates.

Ensure dosing submitted matches U.S. FDA‑labeled dosing for the specific indication (e.g., RA, GCA, PJIA, SJIA, CRS).
Reference the policy's Summary of Changes (03/01/2026) when the request relies on interpretation of non‑preferred product status or updated examples of systemic targeted immunomodulators.
Include prescriber attestations when required (e.g., inability of patient/caregiver to self‑administer IV vs subcutaneous formulations).

Step Therapy

RA Step Therapy: Non‑Biologic DMARD Requirement and DMARD Sequencing Context

For rheumatoid arthritis, prior failure, contraindication, or intolerance to at least one non‑biologic DMARD is required before tocilizumab is authorized for initial therapy. This is consistent with guideline‑based DMARD sequencing and treat‑to‑target approaches.

Examples of non‑biologic DMARDs include methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, and minocycline.
When asserting prior failure, include dates, agents, doses, duration, and reason for discontinuation (lack of efficacy, intolerance, or contraindication).
The policy recognizes sequencing within a treat‑to‑target framework; documentation that a treat‑to‑target strategy was attempted or considered (for example ACT‑RAY trial strategies or 2021 ACR guideline recommendations) may support escalation to tocilizumab.

Authorization limitInitial authorization for CRS is limited to no more than 4 doses per the policy and NCCN dosing assessment guidance.

inv-45: Steroid-refractory acute GVHD

DefinitionSteroid-refractory acute GVHD: acute graft-versus-host disease that does not respond to systemic corticosteroids.

Coverage contextTocilizumab is covered when used in combination with systemic corticosteroids for steroid-refractory acute GVHD or when the patient is intolerant to systemic corticosteroid therapy.

Authorization limitInitial authorization is limited to no more than 4 doses for acute GVHD per the policy.

inv-46: Tocilizumab mechanism

Mechanism of actionInterleukin-6 (IL-6) receptor antagonist: tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors and inhibits IL-6–mediated signaling.

Biologic classRecombinant humanized anti-human IL-6 receptor monoclonal antibody.

Pathophysiologic relevanceBy inhibiting IL-6 signaling, TCZ modulates inflammatory pathways involved in rheumatoid arthritis and other inflammatory conditions.

inv-47: DAS28-ESR

DefinitionDAS28-ESR: Disease Activity Score in 28 joints using the erythrocyte sedimentation rate; used as a disease activity metric and endpoint in TCZ trials (e.g., ACT-RAY).

Use in trialsEmployed to guide treat-to-target strategies and to define remission, flare, and need for treatment adaptation in ACT-RAY.

Remission cutoffRemission defined as DAS28-ESR < 2.6 in trial analyses.

inv-48: CRS

Short term indexCRS (Cytokine Release Syndrome)

AcronymCRS = Cytokine Release Syndrome

ContextOccurs after cellular or certain immunotherapies and is an established indication context for tocilizumab per NCCN and FDA labeling.

inv-49: DMARD

DefinitionDMARD: disease-modifying antirheumatic drug, encompassing conventional synthetic (csDMARD), biologic (bDMARD), and targeted synthetic (tsDMARD) agents used to treat rheumatoid arthritis and related conditions.

Examples of classescsDMARDs (e.g., methotrexate, sulfasalazine), bDMARDs (e.g., tocilizumab as a biologic), tsDMARDs (targeted small molecules), per ACR guideline terminology.

Role in sequencingACR guidelines and policy emphasize DMARD sequencing and treat-to-target approaches when considering initiation of biologic DMARDs like tocilizumab.

The policy's preferred-product section was updated to indicate that any FDA‑approved tocilizumab product not listed by name in the policy will be treated as non-preferred until reviewed by UnitedHealthcare; this language was added to clarify how newly approved or otherwise unlisted tocilizumab products will be handled for coverage purposes.